AI Generated Image
Closely watched Pfizer lung cancer drug falls short in clinical trial
statnews.com • • business
Key Points:
- Pfizer announced that its experimental drug sigvotatug vedotin did not meet expectations in a clinical trial aimed at replacing the chemotherapy drug docetaxel for lung cancer treatment.
- Docetaxel, approved in 1996, is a widely used chemotherapy for one of the most common forms of lung cancer, and sigvotatug vedotin was hoped to be a superior alternative.
- Pfizer’s CEO Albert Bourla had previously highlighted the drug as a potential significant growth driver for the company later this decade.
- Analysts and medical professionals had expressed optimism about the drug’s potential prior to the trial results, marking the data readout as a major event in oncology.
